Madison Muller

Kagrisemma was supposed to be the next thing for Novo to help it compete with Zepbound.

And so they ran this head-to-head trial between Zepbound and Kagrisemma, and Kagrisemma

The expectations were that they would maybe be on par with each other.

But what we saw was that Cagrosema actually wasn't as effective as Zepan, which sort of dashes Novo's hopes for this next generation drug.

Novo is suing on the grounds of patent infringement, which is something we haven't seen before.

Novo and Lilly have both filed lawsuits against compounding pharmacies, telehealth companies, med spas that are selling these knockoff versions of the drugs, but they haven't gone after anyone for patent infringement yet.

So this is actually the drug semaglutide, which is the active ingredient in both Ozempic and Wagovi.

Novo is saying that HIMSS is violating that patent in the United States.

Novo is suing on the grounds of patent infringement, which is something we haven't seen before.

Novo and Lilly have both filed lawsuits against compounding pharmacies, telehealth companies, med spas that are selling these knockoff versions of the drugs, but they haven't gone after anyone for patent infringement yet.

So this is actually the drug semaglutide, which is the active ingredient in both Ozempic and Wagovi.

Novo is saying that HIMS is violating that patent in the United States.

Novo is suing on the grounds of patent infringement, which is something we haven't seen before.

Novo and Lilly have both filed lawsuits against compounding pharmacies, telehealth companies, med spas that are selling these knockoff versions of the drugs, but they haven't gone after anyone for patent infringement yet.

So this is actually the drug semaglutide, which is the active ingredient in both Ozempic and Wagovi.

Novo is saying that HIMSS is violating that patent in the United States.

Novo is suing on the grounds of patent infringement, which is something we haven't seen before.

Novo and Lilly have both filed lawsuits against compounding pharmacies, telehealth companies, med spas that are selling these knockoff versions of the drugs, but they haven't gone after anyone for patent infringement yet.

So this is actually the drug semaglutide, which is the active ingredient in both Ozempic and Wagovi.

Novo is saying that HIMS is violating that patent in the United States.